Peptonic Medical AB (publ) ("Peptonic" or the "Company") has received a new order under the Company's partnership agreement with an established US player in intimate self-care for women during and after menopause. The agreement covers the markets of the United States, Canada, Mexico and the United Kingdom and entails Peptonic supplying products that are marketed and sold under the partner's own well-established brand, i.e. as white-label products.
The new order follows the initial order of approximately USD 120,000 received by Peptonic in October 2025 and represents a further step in the commercial collaboration between the parties. Following a successful launch of the product in the partner's markets during the summer, the partner has now requested to place a new order of approximately the same size as the first.
- The new order is a positive confirmation of our collaboration. The fact that the partnership is now continuing with an additional order reinforces our confidence in the potential to build long-term, scalable growth together with established players in strategically important markets, says Daniel Rudeklint, interim CEO of Peptonic Medical.
For further information, please contact:
Daniel Rudeklint, interim CEO, Peptonic Medical AB
Email: daniel.rudeklint@peptonicmedical.se
Phone: +46 73 158 02 73
About Peptonic Medical AB
Peptonic Medical AB (publ) is a Swedish medical technology company that develops and sells clinically proven self-care products in women's intimate health. Under the VagiVital and Vernivia brands, the Company offers an over-the-counter portfolio of effective and gentle products that help women understand, treat and prevent common intimate medical conditions. Peptonic's growth strategy is based on geographic expansion, particularly in the United States and Europe, and on continuously strengthening its product portfolio through in-house product development and strategic acquisitions.